Form 8-K - Current report:
SEC Accession No. 0001935979-25-000026
Filing Date
2025-04-28
Accepted
2025-04-28 07:59:17
Documents
15
Period of Report
2025-04-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20250428.htm   iXBRL 8-K 41886
2 EX-10.1 exhibit101notepurchaseagre.htm EX-10.1 1021607
3 EX-99.1 exhibit9912025oberlandpres.htm EX-99.1 18007
  Complete submission text file 0001935979-25-000026.txt   1389785

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20250428.xsd EX-101.SCH 1803
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20250428_lab.xml EX-101.LAB 21597
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20250428_pre.xml EX-101.PRE 12510
18 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20250428_htm.xml XML 2706
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Ltd. (Filer) CIK: 0001935979 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41477 | Film No.: 25875978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)